The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Qiliqiangxin · Qiliqiangxin · Heart failure with reduced ejection fraction · Heart failure with reduced ejection fraction · NT-proBNP · Left ventricular ejection fraction · Heart failure hospitalization · Cardiovascular mortality · composite primary outcome · All-cause mortality · traditional Chinese medicine · standard heart failure therapy · hazard ratio · multicenter trial · China
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459